198 related articles for article (PubMed ID: 36229529)
1. Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: The potential importance of post-treatment plasma renin levels.
Yoshida Y; Fujiki R; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Mori Y; Matsuda N; Noguchi T; Nakama H; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2023 Jan; 46(1):100-107. PubMed ID: 36229529
[TBL] [Abstract][Full Text] [Related]
2. Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
Fountoulakis S; Papanastasiou L; Voulgaris N; Kounadi T; Markou A; Chrousos GP; Piaditis G
Hormones (Athens); 2020 Jun; 19(2):223-232. PubMed ID: 31863347
[TBL] [Abstract][Full Text] [Related]
3. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
5. Prediction of endogenous mineralocorticoid receptor activity by depressor effects of mineralocorticoid receptor antagonists in patients with primary aldosteronism.
Ikemoto M; Morimoto S; Ichihara A
Hypertens Res; 2024 Jun; 47(6):1707-1718. PubMed ID: 38548912
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
7. Moderate dietary salt restriction improves blood pressure and mental well-being in patients with primary aldosteronism: The salt CONNtrol trial.
Schneider H; Sarkis AL; Sturm L; Britz V; Lechner A; Potzel AL; Müller LM; Heinrich DA; Künzel H; Nowotny HF; Seiter TM; Kunz S; Bidlingmaier M; Reincke M; Adolf C
J Intern Med; 2023 Jul; 294(1):47-57. PubMed ID: 36945842
[TBL] [Abstract][Full Text] [Related]
8. Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism.
Nomura M; Kurihara I; Itoh H; Ichijo T; Katabami T; Tsuiki M; Wada N; Yoneda T; Sone M; Oki K; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Inagaki N; Yamamoto K; Otsuki M; Yabe D; Izawa S; Takahashi Y; Suzuki T; Yasoda A; Tanabe A; Naruse M;
Hypertens Res; 2022 Sep; 45(9):1476-1485. PubMed ID: 35764671
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study.
Nishimoto M; Ohtsu H; Marumo T; Kawarazaki W; Ayuzawa N; Ueda K; Hirohama D; Kawakami-Mori F; Shibata S; Nagase M; Isshiki M; Oba S; Shimosawa T; Fujita T
Hypertens Res; 2019 Apr; 42(4):514-521. PubMed ID: 30631161
[TBL] [Abstract][Full Text] [Related]
10. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
12. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
[TBL] [Abstract][Full Text] [Related]
13. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
[TBL] [Abstract][Full Text] [Related]
14. Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.
Katsuragawa S; Goto A; Shinoda S; Inoue K; Nakai K; Saito J; Nishikawa T; Tsurutani Y
Hypertension; 2023 Sep; 80(9):1909-1920. PubMed ID: 37449450
[TBL] [Abstract][Full Text] [Related]
15. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Lales G; Mitas C; Doumas M
Curr Pharm Des; 2018; 24(46):5508-5516. PubMed ID: 30854950
[TBL] [Abstract][Full Text] [Related]
17. Association of aldosterone and blood pressure with the risk for cardiovascular events after treatments in primary aldosteronism.
Haze T; Hirawa N; Yano Y; Tamura K; Kurihara I; Kobayashi H; Tsuiki M; Ichijo T; Wada N; Katabami T; Yamamoto K; Oki K; Inagaki N; Okamura S; Kai T; Izawa S; Yamada M; Chiba Y; Tanabe A; Naruse M
Atherosclerosis; 2021 May; 324():84-90. PubMed ID: 33831673
[TBL] [Abstract][Full Text] [Related]
18. Appropriate mineralocorticoid receptor antagonism and salt restriction are essential for primary aldosteronism therapy.
Sawami K; Tanaka A; Node K
Hypertens Res; 2023 Mar; 46(3):794-796. PubMed ID: 36609497
[No Abstract] [Full Text] [Related]
19. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
[TBL] [Abstract][Full Text] [Related]
20. Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension.
Mansur A; Vaidya A; Turchin A
Am J Hypertens; 2023 Jul; 36(8):455-461. PubMed ID: 37013957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
